Lupin is currently trading at Rs. 848.00, up by 5.20 points or 0.62% from its previous closing of Rs. 842.80 on the BSE.
The scrip opened at Rs. 841.00 and has touched a high and low of Rs. 855.00 and Rs. 840.50 respectively. So far 54725 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 857.55 and Rs. 803.00 respectively. The current market cap of the company is Rs. 38288.86 crore.
The promoters holding in the company stood at 47.00%, while Institutions and Non-Institutions held 37.69% and 15.30% respectively.
Lupin has received tentative approval for its Tadalafil Tablets USP, 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and Company's (Lilly) Adcirca Tablets, 20 mg. Adcirca Tablets, 20 mg, had annual sales of approximately $503.8 million in the US (IQVIA MAT Sept ember 2018).
Lupin's Tadalafil Tablets USP, 20 mg is the generic version of Lilly's Adcirca Tablets, 20 mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |